Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2023-01-09 | Reverse | 1:10 |
| 2016-03-24 | Reverse | 1:6 |
Alterity Therapeutics Limited, based in Melbourne, develops drugs for neurological disorders like Alzheimer's, Parkinson's, and Huntington's, with lead candidates ATH434 and PBT2 having completed Phase I and IIa trials respectively.
ATH434, Alterity Therapeutics' lead oral small molecule, aims to treat Multiple System Atrophy by redistributing brain iron to reduce α-synuclein aggregation, potentially serving as a first-in-class, disease-modifying therapy.
In early 2025, Alterity Therapeutics announced positive topline data from its ATH434-201 and ATH434-202 Phase 2 clinical trials, demonstrating that its lead drug candidate showed clinically meaningful benefits and a favorable safety profile in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder. This pivotal development positioned ATH434 as a potential first-in-class therapy for a condition with high unmet medical need and was a crucial step towards late-stage regulatory development.
Alterity Therapeutics successfully raised A$20.0 million through a strategic placement of shares to international and Australian professional investors. This capital infusion is a direct result of positive topline data from the Phase 2 clinical trials of their lead drug candidate, ATH434, for Multiple System Atrophy (MSA), and is intended to fund the next crucial steps towards regulatory approval and commercialization.
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 ANVS | $1.15 | COMPARE |
 EVAX | $3.09 | COMPARE |
 DYAI | $0.44 | COMPARE |
 LIMN | $3.63 | COMPARE |
